ADORA2A and COVID-19: A recent related preclinical COVID-19 study and clinical results of partly iNKT-acting adenosine A2A receptor agonist (Regadenoson) in COVID-1942,43, as well the current clinical study provide compelling evidence to support randomized clinical studies of iNKT cell-based therapy in severe acute infectious settings including critically unwell individuals, as described here.